Eptifibatide infusion versus placebo in high risk patients with non-st segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. a prospective multicenter randomized placebo-controlled clinical trial.
CONCLUSION: Preoperative use of eptifibatide vs. placebo is linked to significantly reduced 12--month MACCE rate in patients with NSTE--ACS requiring urgent CABG, while it simultaneously seems not to confer a greater risk of postoperative bleeding.
PMID: 25394877 [PubMed - as supplied by publisher] (Source: The Journal of Cardiovascular Surgery)
Source: The Journal of Cardiovascular Surgery - November 14, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Wilczynski M, Wybraniec MT, Milewski K, Sanak M, Wita K, Buldak L, Kondys M, Buszman P, Bochenek A Tags: J Cardiovasc Surg (Torino) Source Type: research
Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions
Conclusions • Platelet aggregation inhibition during PCI was significantly correlated with STR and MBG. Platelet aggregation inhibition cut-off point as a predictor of STR >70% was 89.5%, and as a predictor of MBG 2–3 was 87.5%. • Eptifibatide achieves better platelet aggregation inhibition 60min after bolus and 6h after PCI than high dose Tirofiban. • Eptifibatide is associated with better myocardial perfusion as indicated by post procedural mean MBG and STR >70% than high dose Tirofiban. • There was no significant differences between Eptifibatide and high dose Tirofiban regarding thromboc...
Source: The Egyptian Heart Journal - November 6, 2014 Category: Cardiology Source Type: research
Administration of eptifibatide during endovascular treatment of ruptured cerebral aneurysms reduces the rate of thromboembolic events
Conclusion
Eptifibatide was effective in lowering the intraoperative thromboembolic complication rate in ruptured aneurysms treated with coil embolization and did not increase the hemorrhagic risk. (Source: Neuroradiology)
Source: Neuroradiology - October 18, 2014 Category: Radiology Source Type: research
Platelet mapping assay interference due to platelet activation in heparinized samples.
CONCLUSIONS: Unanticipated platelet activation/aggregation occurring in the heparinized TEGPM samples lead to erroneous percent inhibition results.
PMID: 25125623 [PubMed - in process] (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - August 19, 2014 Category: Pathology Authors: Nelles NJ, Chandler WL Tags: Am J Clin Pathol Source Type: research
αIIbβ3-Integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells.
This study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic ...
Source: Current Drug Targets - August 4, 2014 Category: Drugs & Pharmacology Authors: Kononczuk J, Surazynski A, Czyzewska U, Prokop I, Tomczyk M, Palka J, Miltyk W Tags: Curr Drug Targets Source Type: research
P-008 Loading Doses of Aspirin and Clopidogrel Prior to Enterprise Stent-assisted Repair of Intracranial Aneurysm-A Single Center Experience
Conclusions
Using loading doses of aspirin and clopidogrel in Enterprise stent-assisted repair of intracranial aneurysm is not only safe and feasible but associated with good clinical outcome. Therefore, loading doses of aspirin and clopidogrel is an alternative option for patients who are candidates for stent-assisted repair of intracranial aneurysm.
Disclosures
Y. Lodi: None. V. Reddy: None. A. Devasenapathy: None. J. Chou: None. K. Shehades: None. K. Sethi: None. D. Galyon: None. S. Bajwa: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 26, 2014 Category: Neurosurgery Authors: Lodi, Y., Reddy, V., Devasenapathy, A., Chou, J., Shehades, K., Sethi, K., Galyon, D., Bajwa, S. Tags: Oral poster abstracts Source Type: research
Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS
Antiphospholipid syndrome (APS) is defined by thrombosis, fetal loss, and the presence of antiphospholipid antibodies, including anti–β2-glycoprotein-1 autoantibodies (anti-β2GP1) that have a direct role in the pathogenesis of thrombosis in vivo. The cellular targets of the anti-β2GP1 autoantibody/β2GP1 complex in vivo were studied using a laser-induced thrombosis model of APS in a live mouse and human anti-β2GP1 autoantibodies affinity-purified from APS patients. Cell binding of fluorescently labeled β2GP1 and anti-β2GP1 autoantibodies revealed their colocalization on the platelet ...
Source: Blood - July 24, 2014 Category: Hematology Authors: Proulle, V., Furie, R. A., Merrill-Skoloff, G., Furie, B. C., Furie, B. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis Source Type: research
A potent anti-thrombosis peptide (vasotab TY) from horsefly salivary glands.
Abstract
Vasotab TY is a KGD (Lys-Gly-Asp)-containing peptide identified from salivary glands of the horsefly of Tabanus yao. We have previously reported that vasotab TY showed a strong vasodilator activity. In the present study, vasotab TY was found to inhibit platelet aggregation effectively. It completely inhibited platelet aggregation induced by adenosine diphosphate (ADP) at the concentration of 9.6μg/ml. Vasotab TY significantly reduced thrombus weight in rat arteriovenous shunt model and inhibited thrombosis in carrageenan-induced mouse tail thrombosis model in vivo. Vasotab TY competitively bound ...
Source: The International Journal of Biochemistry and Cell Biology - July 12, 2014 Category: Biochemistry Authors: Zhang Z, Gao L, Shen C, Rong M, Yan X, Lai R Tags: Int J Biochem Cell Biol Source Type: research
Restoration of ovarian function and natural fertility following the cryopreservation and autotransplantation of whole adult sheep ovaries
STUDY QUESTION
Is it possible to restore ovarian function and natural fertility following the cryopreservation and autotransplantation of whole ovaries, complete with vascular pedicle, in adult females from a large monovulatory animal model species (i.e. sheep)?
SUMMARY ANSWER
Full (100%) restoration of acute ovarian function and high rates of natural fertility (pregnancy rate 64%; live birth rate 29%), with multiple live births, were obtained following whole ovary cryopreservation and autotransplantation (WOCP&TP) of adult sheep ovaries utilizing optimized cryopreservation and post-operative anti-coagulant regimes.
...
Source: Human Reproduction - July 10, 2014 Category: Reproduction Medicine Authors: Campbell, B. K., Hernandez-Medrano, J., Onions, V., Pincott-Allen, C., Aljaser, F., Fisher, J., McNeilly, A. S., Webb, R., Picton, H. M. Tags: Reproductive biology Source Type: research
Safety of eptifibatide when added to bivalirudin during ST-segment elevation myocardial infarction
Patients presenting with ST-segment elevation myocardial infarction (STEMI) represent a high-risk group for in-hospital adverse events and bleeding. The safety and outcomes of eptifibatide in addition to bivalirudin in this population have not been determined. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 10, 2014 Category: Cardiology Authors: Nevin C. Baker, Ricardo O. Escarcega, Marco A. Magalhaes, Michael J. Lipinski, Rebecca Torguson, Ron Waksman Tags: Clinical Source Type: research
Safety of Eptifibatide When Added to Bivalirudin during ST-segment Elevation Myocardial Infarction
(Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 10, 2014 Category: Cardiology Authors: Nevin C. Baker, Ricardo O. Escarcega, Marco A. Magalhaes, Michael J. Lipinski, Rebecca Torguson, Ron Waksman Source Type: research
Combination Therapy of Intravenous Glycoprotein IIB-IIIA Inhibitors and Tissue Plasminogen Activator for Acute Ischemic Stroke (P1.112)
Conclusion Combination of low dose IV tPA with GpIIb/IIIa inhibitor is associated with better functional outcome at 90 days as well as reduction in sICH rates in patients with acute ischemic stroke as compared to 0.9g/kg IVtPA.Disclosure: Dr. Sawhney has nothing to disclose. Dr. Dubey has nothing to disclose. Dr. Banerjee has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sawhney, A., Dubey, D., Banerjee, C. Tags: Cerebrovascular Disease and Interventional Neurology: Antiplatelet Agents and Miscellaneous Source Type: research
Eptifibatide: The evidence for its role in the management of acute coronary syndromes
Shah I, Khan SO, Malhotra S, Fischell T (Source: Core Evidence)
Source: Core Evidence - March 14, 2014 Category: Drugs & Pharmacology Source Type: research
Eptifibatide: The evidence for its role in the management of acute coronary syndromes [Corrigendum]
(Source: Core Evidence)
Source: Core Evidence - March 13, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
